|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,788,000 |
Market
Cap: |
2.28(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$14.19 - $52.31 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. Co. is developing ARV-110, a proteolysis targeting chimeras (PROTAC) targeted protein degrader targeting the androgen receptor protein for the treatment of men with metastatic castration-resistant prostate cancer. Co. is also developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
10,298 |
11,622 |
21,554 |
Total Sell Value |
$0 |
$484,521 |
$516,810 |
$859,747 |
Total People Sold |
0 |
4 |
4 |
4 |
Total Sell Transactions |
0 |
4 |
5 |
9 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Young John D |
Director |
|
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,899 |
10,020 |
|
- |
|
Morrison Briggs |
Director |
|
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,899 |
29,996 |
|
- |
|
Cunningham Everett |
Director |
|
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,899 |
10,020 |
|
- |
|
Bain Linda |
Director |
|
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,899 |
10,020 |
|
- |
|
Norwalk Leslie V |
Director |
|
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,899 |
10,020 |
|
- |
|
Kennedy Edward Moore Jr. |
Director |
|
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,899 |
23,405 |
|
- |
|
Smaldone Alsup Laurie |
Director |
|
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,899 |
10,020 |
|
- |
|
Agarwal Sunil |
Director |
|
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,899 |
14,141 |
|
- |
|
Teel Randy |
Int. Chief Financial Officer |
|
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
13,300 |
59,341 |
|
- |
|
Berkowitz Noah |
Chief Medical Officer |
|
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
63,452 |
63,452 |
|
- |
|
Teel Randy |
Int. Chief Financial OfficerOf |
|
2024-02-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
46,041 |
|
-30% |
|
Taylor Ian |
Chief Scientific Officer |
|
2024-02-23 |
4 |
S |
$47.05 |
$80,032 |
D/D |
(1,701) |
147,522 |
|
31% |
|
Taylor Ian |
Chief Scientific Officer |
|
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
39,250 |
149,223 |
|
- |
|
Peck Ronald |
Chief Medical Officer |
|
2024-02-23 |
4 |
S |
$47.05 |
$79,938 |
D/D |
(1,699) |
67,516 |
|
31% |
|
Peck Ronald |
Chief Medical Officer |
|
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
39,250 |
69,215 |
|
- |
|
Houston John G |
President and CEO |
|
2024-02-23 |
4 |
S |
$47.05 |
$244,472 |
D/D |
(5,196) |
1,036,681 |
|
31% |
|
Houston John G |
President and CEO |
|
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
124,450 |
1,041,877 |
|
- |
|
Loomis David K |
Chief Accounting Officer |
|
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
5,750 |
8,500 |
|
- |
|
Cassidy Sean A |
Chief Financial Officer |
|
2024-02-23 |
4 |
S |
$47.05 |
$80,079 |
D/D |
(1,702) |
181,916 |
|
31% |
|
Taylor Ian |
Chief Scientific Officer |
|
2024-01-04 |
4 |
OE |
$16.00 |
$132,032 |
D/D |
8,252 |
109,973 |
|
- |
|
Peck Ronald |
Chief Medical Officer |
|
2023-08-11 |
4 |
S |
$24.39 |
$32,289 |
D/D |
(1,324) |
29,965 |
|
-52% |
|
Peck Ronald |
Chief Medical Officer |
|
2023-08-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,010 |
31,289 |
|
- |
|
Houston John G |
President and CEO |
|
2023-03-01 |
4 |
S |
$29.53 |
$173,577 |
D/D |
(5,878) |
917,427 |
|
25% |
|
Houston John G |
President and CEO |
|
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,510 |
923,305 |
|
- |
|
Cassidy Sean A |
Chief Financial Officer |
|
2023-03-01 |
4 |
S |
$29.53 |
$51,530 |
D/D |
(1,745) |
183,618 |
|
25% |
|
183 Records found
|
|
Page 1 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|